Download PDF
Rofo 2023; 195(01): 30-37
DOI: 10.1055/a-1858-3418
Interventional Radiology

Chemosaturation of the Liver – an Update

Article in several languages: English | deutsch
Sebastian Ebel 
1   Klinik und Poliklinik für diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany
,
Manuel Florian Struck 
2   Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Leipzig University, Leipzig, Germany
,
Florian van Boemmel
3   Klinik für Innere Medizin II, Sektion für Hepatologie, Leipzig University, Leipzig, Germany
,
Anne Bettina Beeskow
1   Klinik und Poliklinik für diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany
,
Holger Gößmann
1   Klinik und Poliklinik für diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany
,
Timm Denecke
1   Klinik und Poliklinik für diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Percutaneous hepatic perfusion (CS-PHP) is a treatment option for primary and secondary liver neoplasms and subject of intensive research. This present article provides an overview of CS-PHP regarding patient safety, feasibility and effectiveness based on recent studies.

Method We performed a PubMed search including the search terms chemosaturation, hepatic chemosaturation, percutaneous perfusion and melphalan.

Results and conclusion CS-PHP is a promising procedure for the treatment of uveal melanoma and cholangiocellular carcinoma. There are insufficient data regarding the effectiveness of CS-PHP with respect to other tumor entities. Since CS-PHP can be accompanied by multiple transient side effects and complications, close interdisciplinary cooperation is necessary.

Key Points:

  • Chemosaturation of the liver is a safe procedure.

  • CS-PHP is a potent therapy for hepatic metastatic ocular melanoma and cholangiocellular carcinoma.

  • The procedure requires close interdisciplinary coordination.

  • CS-PHP is a repeatable and thus long-term therapeutic option for some patients.

Citation Format

  • Ebel S, Struck MF, van Boemmel F et al. Chemosaturation of the Liver – an Update. Fortschr Röntgenstr 2023; 195: 30 – 37

Key words

abdomen - hematologic - angiography - interventional procedures


Publication History

Received: 20 September 2021

Accepted: 05 May 2022

Article published online:
17 August 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Inc D Hepatic Delivery System Instructions for Use.
    PubMedGoogle Scholar
  • 2 Meijer TS, Burgmans MC, Fiocco M. et al. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. Cardiovasc Intervent Radiol 2019; 42: 841-852 DOI: 10.1007/s00270-019-02177-x.
    CrossrefPubMedGoogle Scholar
  • 3 Dewald CLA, Meine TC, Winther HMB. et al. Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) with Melphalan: Evaluation of 2D-Perfusion Angiography (2D-PA) for Leakage Detection of the Venous Double-Balloon Catheter. Cardiovasc Intervent Radiol 2019; 42: 1441-1448 DOI: 10.1007/s00270-019-02243-4.
    CrossrefPubMedGoogle Scholar
  • 4 Dewald CLA, Becker LS, Maschke SK. et al. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. Clin Exp Metastasis 2020; 37: 683-692 DOI: 10.1007/s10585-020-10057-9.
    CrossrefPubMedGoogle Scholar
  • 5 Struck MF, Kliem P, Ebel S. et al. Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery. PLoS One 2021; 16 DOI: 10.1371/journal.pone.0254817.
    CrossrefPubMedGoogle Scholar
  • 6 de Leede EM, Burgmans MC, Meijer TS. et al. Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan. Cardiovasc Intervent Radiol 2017; 40: 1196-1205 DOI: 10.1007/s00270-017-1630-4.
    CrossrefPubMedGoogle Scholar
  • 7 Forster MR, Rashid OM, Perez MC. et al. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: A single institution experience. J Surg Oncol 2014; 109: 434-439 DOI: 10.1002/jso.23501.
    CrossrefPubMedGoogle Scholar
  • 8 Dewald CLA, Hinrichs JB, Becker LS. et al. Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgeb Verfahren 2021; 193: 928-936 DOI: 10.1055/a-1348-1932.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Karydis I, Gangi A, Wheater MJ. et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. J Surg Oncol 2018; 117: 1170-1178 DOI: 10.1002/jso.24956.
    CrossrefPubMedGoogle Scholar
  • 10 Marquardt S, Kirstein MM, Brüning R. et al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 2019; 29: 1882-1892 DOI: 10.1007/s00330-018-5729-z.
    CrossrefPubMedGoogle Scholar
  • 11 Vogl TJ, Koch SA, Lotz G. et al. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. Cardiovasc Intervent Radiol 2017; 40: 864-872 DOI: 10.1007/s00270-017-1588-2.
    CrossrefPubMedGoogle Scholar
  • 12 Brüning R, Tiede M, Schneider M. et al. Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan – Long-Term Overall Survival Negatively Correlates with Tumor Burden. Radiol Res Pract 2020; 2020: 1-7 DOI: 10.1155/2020/5672048.
    CrossrefPubMedGoogle Scholar
  • 13 Schönfeld L, Hinrichs JB, Marquardt S. et al. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. J Cancer Res Clin Oncol 2020; 146: 3003-3012 DOI: 10.1007/s00432-020-03289-5.
    CrossrefPubMedGoogle Scholar
  • 14 Vogl TJ, Zangos S, Scholtz JE. et al. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo 2014; 186: 937-944 DOI: 10.1055/s-0034-1366081.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Artzner C, Mossakowski O, Hefferman G. et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: A single center experience. Cancer Imaging 2019; 19: 1-8 DOI: 10.1186/s40644-019-0218-4.
    CrossrefPubMedGoogle Scholar
  • 16 Hughes MS, Zager J, Faries M. et al. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. Ann Surg Oncol 2016; 23: 1309-1319 DOI: 10.1245/s10434-015-4968-3.
    CrossrefPubMedGoogle Scholar
  • 17 Pingpank JF, Libutti SK, Chang R. et al. Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies. J Clin Oncol 2008; 23: 3465-3474 DOI: 10.1021/nn2045246.Multifunctional.
    CrossrefPubMedGoogle Scholar
  • 18 Kirstein MM, Marquardt S, Jedicke N. et al. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol 2017; 143: 2113-2121 DOI: 10.1007/s00432-017-2461-z.
    CrossrefPubMedGoogle Scholar
  • 19 Carr MJ, Sun J, Cohen JB. et al. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases. Cancer Control 2020; 27: 1-9 DOI: 10.1177/1073274820983019.
    CrossrefPubMedGoogle Scholar
  • 20 Ferrucci PF, Cocorocchio E, Bonomo G. et al. A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System. Cells 2021; 10 DOI: 10.3390/cells10010070.
    CrossrefPubMedGoogle Scholar
  • 21 Onkologie L. S3-Leitlinie Früherkennung, Therapie und Nachsorge des Melanomes. 2020: 1-400
    PubMedGoogle Scholar
  • 22 Feldman ED, Pingpank JF, Alexander HR. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004; 11: 290-297 DOI: 10.1245/ASO.2004.07.004.
    CrossrefPubMedGoogle Scholar
  • 23 Jovanovic P, Mihajlovic M, Djordjevic-Jocic J. et al. Ocular melanoma: An overview of the current status. Int J Clin Exp Pathol 2013; 6: 1230-1244
    PubMedGoogle Scholar
  • 24 Gragoudas ES, Egan KM, Seddon JM. et al. Survival of Patents with Metastases from Uveal Melanoma. Ophthalmology 1991; 98: 383-390 DOI: 10.1016/S0161-6420(91)32285-1.
    CrossrefPubMedGoogle Scholar
  • 25 Carvajal RD, Schwartz GK, Tezel T. et al. Metastatic disease from uveal melanoma: Treatment options and future prospects. Br J Ophthalmol 2017; 101: 38-44 DOI: 10.1136/bjophthalmol-2016-309034.
    CrossrefPubMedGoogle Scholar
  • 26 Hawkins BS. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124: 1684-1693
    CrossrefPubMedGoogle Scholar
  • 27 Triozzi PL, Singh AD. Adjuvant Therapy of Uveal Melanoma: Current Status. Ocul Oncol Pathol 2015; 1: 54-62 DOI: 10.1159/000367715.
    CrossrefPubMedGoogle Scholar
  • 28 Khoja L, Atenafu EG, Joshua AM. Meta-analysis of phase II trials in metastatic uveal melanoma (MUM) to determine progression-free (PFS) and overall survival (OS) benchmarks for future phase II trials: An irci-ocular melanoma initiative. J Clin Oncol 2016; 34: 9567 DOI: 10.1200/JCO.2016.34.15\_suppl.9567.
    CrossrefPubMedGoogle Scholar
  • 29 Xing M, Prajapati HJ, Dhanasekaran R. et al. Selective internal yttrium-90 radioembolization therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy. Am J Clin Oncol 2017; 40: 27-34
    CrossrefPubMedGoogle Scholar
  • 30 Memon K, Kuzel TM, Vouche M. et al. Hepatic yttrium-90 radioembolization for metastatic melanoma: A single-center experience. Melanoma Res 2014; 24: 244-251 DOI: 10.1097/CMR.0000000000000051.
    CrossrefPubMedGoogle Scholar
  • 31 Gupta S, Bedikian AY, Ahrar J. et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: Response, survival, and prognostic factors. Am J Clin Oncol Cancer Clin Trials 2010; 33: 474-480 DOI: 10.1097/COC.0b013e3181b4b065.
    CrossrefPubMedGoogle Scholar
  • 32 Ahrar J, Gupta S, Ensor J. et al. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. Cancer Invest 2011; 29: 49-55
    CrossrefPubMedGoogle Scholar
  • 33 Gonsalves CF, Eschelman DJ, Adamo RD. et al. A prospective Phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology 2019; 293: 223-231 DOI: 10.1148/radiol.2019190199.
    CrossrefPubMedGoogle Scholar
  • 34 Veelken R, Maiwald B, Strocka S. et al Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol In Press 2021
    PubMedGoogle Scholar
  • 35 Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int 2019; 39: 19-31 DOI: 10.1111/liv.14095.
    CrossrefPubMedGoogle Scholar
  • 36 Benson AB, D’Angelica MI, Abbott DE. et al. Hepatobiliary cancers, Version 2.2021. JNCCN J Natl Compr Cancer Netw 2021; 19: 541-565 DOI: 10.6004/jnccn.2021.0022.
    CrossrefPubMedGoogle Scholar
  • 37 Rizvi S, Khan SA, Hallemeier CL. et al. Cholangiocarcinoma – evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018; 15: 95-111 DOI: 10.1038/nrclinonc.2017.157.
    CrossrefPubMedGoogle Scholar
  • 38 Weber SM, Jarnagin WR, Klimstra D. et al. Intrahepatic Cholangiocarcinoma: resectability, recurrence pattern, and outcomes1 1No competing interests declared. J Am Coll Surg 2001; 193: 384-391 DOI: 10.1016/S1072-7515(01)01016-X.
    CrossrefPubMedGoogle Scholar
  • 39 Jarnagin WR, Fong Y, DeMatteo RP. et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-519 DOI: 10.1097/00000658-200110000-00010.
    CrossrefPubMedGoogle Scholar
  • 40 Bridgewater J, Galle PR, Khan SA. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60: 1268-1289 DOI: 10.1016/j.jhep.2014.01.021.
    CrossrefPubMedGoogle Scholar
  • 41 Onkologie L. Konsultationsfassung Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome Wesentliche Neuerungen in der Leitlinie zur Diagnostik und Therapie des hepatozellulären Karzinoms. 2021: 1-205
    PubMedGoogle Scholar
  • 42 Akateh C, Ejaz AM, Pawlik TM. et al. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12: 693-708 DOI: 10.4254/wjh.v12.i10.693.
    CrossrefPubMedGoogle Scholar
  • 43 Pingpank JF, Hughes MS, Alexander HR. et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol 2010; 28: LBA8512-LBA8512 DOI: 10.1200/jco.2010.28.18\_suppl.lba8512.
    CrossrefPubMedGoogle Scholar
  • 44 Estler A, Artzner C, Nikolaou K. et al. Vorhersage des Tumoransprechens und Gesamtüberleben nach Chemosaturation bei hepatisch metastasiertem Aderhautmelanom. RöFo – Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgeb Verfahren 2021; 1: 10
    PubMedGoogle Scholar